Navigation Links
Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
Date:8/13/2007

Fluctuations in eye pressure may be associated with a decreasing peripheral field of vision in patients with glaucoma, even if their eye pressure remains low overall, according to a report in the August issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Prevention of further visual field deterioration is a goal of glaucoma therapy, the authors write as background information in the article. Previous studies reported that lowering intraocular pressure (IOP) slowed the advancement of visual field damage in patients with glaucoma. However, even if the IOP can be substantially lowered, reduction of mean [average] and peak IOP does not always prevent progressive visual field deterioration.

Samin Hong, M.D., and colleagues at the Yonsei University College of Medicine, Seoul, Korea, studied 408 eyes of patients (average age 66.5 years) who had undergone a triple procedure to treat glaucoma: phacoemulsification, that involves dissolving and removing the lens; posterior chamber intraocular lens implantation; and trabeculectomy, also known as filtration surgery. All patients had a low IOP after surgery (below 18 milligrams of mercury). Measurements of IOP and visual field were taken for an average of 9.2 years following surgery. Based on the standard deviation (difference from the average) in IOP, the eyes were split into two groups, one with greater fluctuation and one with less.

Throughout the follow-up period, the two groups had the same average IOP, and their visual fields were the same after three months. However, after the last follow-up examination13 years laterthe visual field was significantly worse in the group with greater fluctuation in IOP. The number of patients with progressive visual field loss was significantly larger in the group with more fluctuation.

Our results suggest that glaucomatous visual field damage cannot be stabilized by only lowering the postoperative IOP but also requires reducing the
'/>"/>

Contact: Young Jae Hong, M.D., Ph.D.
yjhong0815@yumc.yonsei.ac
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Fluctuating BP and Stroke Lowered Patient Survival Rate
2. Spouses and other partners lower blood pressure says new research
3. H2O - a cure for low blood pressure
4. Uncontrolled blood pressure
5. Nitric oxide involved in high blood pressure
6. Way to monitor blood pressure
7. Pressure on spine cause problems
8. Aggressive blood pressure treatment needed
9. Blood Pressure Drug may slow wasting in burn victims
10. Borderline blood pressure- possible health risk
11. Patients Pressure Would Result In Overprescription

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...8 Pharmaceutical Resear...e President Ken Johnson released the following sta...: ,, "We are disappointed, but not surprised by...of hardworking Americans as well as nearly half of...who voted against the bill. ,, "While well inte...
(Date:11/8/2009)... Shows Who Sides With Working Families vs. Insuran...swire-USNewswire/ -- On the heels of an historic l... a good, balanced health care reform bill, the Pen...state,s U.S. representatives voted on HR 3962, the...e legislation, which passed Saturday evening by a ...
(Date:11/7/2009)...v. 7 Speaker Nancy Pel....R. 3962, the Affordable Health Care for America A...tonight. Below are the Speaker,s remarks. ,, ...ric moment for our nation and for American familie...nd political philosophy -- as far back as Teddy Ro...
(Date:11/7/2009)...PRNewswire/ -- Calling this a "defining moment" fo...President J. James Rohack, M.D., today addressed m...te and medical specialty societies at the opening ...ere health system reform will top the agenda. ,...81209/AMALOGO ) ,, "Over the next 72 hours, t...
(Date:11/7/2009)...7 The U.S. bishops Nove...es to vote for the Stupak-Ellsworth Amendment to t...-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment ... funding and conscience protections in the Afforda... said. ,, The letter was signed by Cardinal Jus...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...Alseres Pharmaceuticals, Inc. today announced that...ASDAQ Stock Market ("NASDAQ") that for the last 10... listed securities has been below the minimum $35 ...NASDAQ Marketplace Rule 4310(c)(3)(A) or 4310(c)(3...
...scular group practice to use Sage Intergy solution...ition itself for pay-for-performance , , TAMPA, F...scular Institute, a Saginaw-Mich.-based group prac...(PM) and Sage Intergy EHR electronic health reco...
...eveal targets for future treatments , , MO...they have discovered genes in prostate cancer cell...th each other, an occurrence that may initiate the...cer cells, a finding that may serve as a marker fo...
...an Inc. (Nasdaq: MYL ),today announced that its ...onal U.S. patents protecting the company,s Perforo... pulmonary disease (COPD) treatment. , U.S. Pa...ormoterol. This patent covers Dey,s Perforomist(R)...
...publication of its kind aimed at healthcare fraud ...e Insight(R) (HCI), a Verisk HealthCare company an... and overpayment prevention solutions for healthca...lication dedicated to helping public and private s...
... Boehringer Ingelheim today announced the appoint...Sales and Marketing for the company,s Prescription...ad the U.S. sales and marketing strategy of Boehri...ef Executive Officer, Boehringer Ingelheim Corpora...
Other Medicine News:Health News:Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements 2Health News:Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements 3Health News:Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements 4Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 2Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 3Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 4Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 5Health News:U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution 2Health News:HealthCare Insight(R) Launches Industry Fraud Magazine 2Health News:Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines 2
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 1Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 4Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 1Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3
...Company Planning to Initiate Phase 2 Trials in Col...Cancer in Q307 -, SOUTH SAN FRANCISCO, Calif., Jun...aceuticals, Inc. , a,biopharmaceutical company foc...s from an interim safety analysis of two Phase 1,d...ion platinum for,the potential first-line treatmen...
...ven year follow up of pivotal trial confirms that ...EL, Switzerland, June 4, 2007-A follow-up analysis...non-Hodgkin,s lymphoma,(NHL) who were treated with...) over seven years ago has revealed exciting resul...ase III study has shown,that over half (53%) of th...
Other Medicine Technology:Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 2MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 4
RNA1c Control for Bayer DCA 2000 and 2000 + Analyzers
Molteno3 Glaucoma Drainage Device
...s a reagent and probe system used together to quan...t plate based system is a sandwich nucleic acid hy...for RNA detection and quantification, by amplifyin...chnology. Branched DNA allows immediate quantifica...
Cormet Hip Resurfacing System
Medicine Products: